Fed. Circ. Questions If Safer OxyContin Profits Came From IP

By Dani Kass · October 7, 2024, 9:39 PM EDT

An attorney for Purdue Pharma didn't seem to find much purchase at the Federal Circuit on Monday as he argued that the company's patents for abuse-deterrent OxyContin weren't obvious, claiming other...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Related Sections

Case Information

Case Title

Purdue Pharma L.P. v. Accord Healthcare, Inc.

Case Number

23-1953

Court

Appellate - Federal Circuit

Nature of Suit

835 Patent - (ANDA) (Fed. Qst.)

Date Filed

May 30, 2023

Featured Stories

23andMe Ch. 11 Sale Sparks DNA Privacy Oversight Battle No Photo Available

Clara Geoghegan

The bankrupt ancestry testing company 23andMe, more than two dozen state attorneys general, and the federal government agree on one th... (more story)

Meet The Attys Leading Global Clean Energy In Ch. 11 No Photo Available

Yun Park

A group of lawyers from Norton Rose Fulbright and Kirkland & Ellis LLP is representing renewable fuel company Global Clean Energy Hold... (more story)

Data Breach, Market Challenges Led 23andMe To Ch. 11 No Photo Available

Yun Park

Facing macroeconomic headwinds, including rising inflation and expenses associated with a major data breach in October 2023, genetic t... (more story)